GW Pharma and New York State to initiate trials of cannabidiol in epilepsy – The Pharma Letter

UK-based GW Pharmaceuticals (Nasdaq: GWPH), a biopharmaceutical company focused on developing novel therapeutics from its proprietary cannabinoid product platform, has welcomed an agreement with New York State to initiate clinical trials using cannabidiol (CBD) to help treat children diagnosed with epilepsy who suffer from seizures and other medical complications.

New York State Governor Andrew Cuomo announced that New York will be the second state in the USA to initiate trials for cannabidiol for children whose medical conditions have not been successfully treated by other methods.

“No child should be forced to live with the heart-breaking effects of medication-resistant epilepsy,” Governor Cuomo said. “Young New Yorkers battling these diseases deserve treatments that work for them, and by investigating the merits of cannabidiol we are pushing the boundaries of modern medicine and working to fundamentally improve the quality of life for those children. I am very hopeful that this research collaboration will grow our understanding of these types of medications and ultimately help New Yorkers lead better lives.”

Aim for FDA filing

The New York State Department of Health (DOH) will take the lead in developing the clinical trial for submission to the US Food and Drug Administration. GW Pharmaceuticals will provide consultative advice and commit personnel and other resources to the partnership, including a supply of Epidiolex, for childhood epilepsy. Designed to be conducted at New York-based hospitals, universities and medical colleges, the clinical trial will address a critical healthcare priority while expanding the scientific community’s understanding of potential treatments for children with medication-resistant epilepsies.

Geoffrey Guy, chairman of GW Pharmaceuticals, said: “We are pleased to be partnering with the State of New York in this ground-breaking program designed to establish a scientific foundation that expands the understanding of how CBD works in children with treatment-resistant epilepsies. This collaboration with the State of New York builds on the foundation established by our relationship with New York University’s Langone Medical Center where 60 children are already authorized by the FDA to receive Epidiolex.”

This entry passed through the Full-Text RSS service — if this is your content and you’re reading it on someone else’s site, please read the FAQ at